Immunotherapy Resistance in Glioblastoma

Glioblastoma is the most common malignant primary brain tumor in adults. Despite treatment consisting of surgical resection followed by radiotherapy and adjuvant chemotherapy, survival remains poor at a rate of 26.5% at 2 years. Recent successes in using immunotherapies to treat a number of solid an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Elaina J., Chen, Jia-Shu, Jain, Saket, Morshed, Ramin A., Haddad, Alexander F., Gill, Sabraj, Beniwal, Angad S., Aghi, Manish K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718605/
https://www.ncbi.nlm.nih.gov/pubmed/34976006
http://dx.doi.org/10.3389/fgene.2021.750675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718605/
https://www.ncbi.nlm.nih.gov/pubmed/34976006
http://dx.doi.org/10.3389/fgene.2021.750675

Ejemplares similares